AG Schmid / Akromegalie
→ Wir arbeiten auf dem Gebiet der Endokrinologie, speziell an endokrinen Tumoren, insbesondere der Hypophyse (Akromegalie), der Nebenschilddrüsen (Hyperparathyreoidismus) und des Pankreas (Insulinom)
 |
Prof. Dr. med. Christoph Schmid Tel +41 44 255 36 20 Fax +41 44 255 97 41 Email
christoph.schmid@usz.ch
Klinische Tätigkeit auf dem gesamten Gebiet der klinischen Endokrinologie, einschliesslich Diabetes, Fett- und Knochen-Stoffwechsel, Elektrolyt- und Mineral-Haushalt. Schwerpunkte: Konsiliarische Tätigkeit im Universitätsspital Zürich, Beratung auswärtiger Ärzte und eigene Sprechstunde zur Betreuung ambulanter Patienten.
|
Research Topics

Effect of GH-secreting pituitary adenomas on circulating levels of IGF1 and sKlotho.
(A) Before surgery, there is a GH-secreting tumour in the pituitary gland. Excessive GH directly acts on the liver (predominant source of IGF1), and the increased production of IGF1 results in increased serum IGF1 levels (mean±S.E.M., 0.58±0.03 mg/l, measured by gold-standard RIA after separation from IGFBPs). Excessive GH also results in increased serum sKlotho levels (4.1±0.4 ng/ml, as detected by the Yamazaki–ELISA). The mechanism (direct/indirect) by which GH excess results in increased (presumably kidney-derived) sKlotho in the circulation remains to be elucidated. The number of both IGF1 particles (small yellow circles) and sKlotho particles (green bars) is markedly increased, by factors of ~ 3 and ~ 5, respectively.
(B) After removal of the GH-secreting adenoma, GH action is normal; IGF1 (0.20±0.01 mg/l) and sKlotho (0.8±0.1 ng/ml) levels returned towards normal.
Data from 50 patients with acromegaly; figure from Ch. Schmid et al. (2013) Growth Hormone and Klotho. Journal of Endocrinology 219:R37-R57.